JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has granted final approval for the Company’s Abbreviated New Drug Application (ANDA) to market Terbinafine Hydrochloride Tablets, 250 mg (base), the AB-rated generic equivalent of Novartis’ antifungal agent Lamisil® Tablets. Shipment of this product will begin immediately.
